News
$Galmed Pharmaceuticals (GLMD.US)$ Galmed Announces Grant Of New Patent For Combination Of Aramchol With Resmetirom (MGL-3196, REZDIFFRA) For Treatment Of NASH And Liver Fibrosis
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : Inventiva said the Phase 2 proof-of-concept study met its primary endpoint with an absolute reduction of HbA1c of 1.14% to 1.59% in patients treated with lanifibranor or in combination with empagliflozin at week 24 versus an increase of 0.26% in the placebo arm.
Patients treated with the combination also were able to maintain a stable weight throughout the 24 weeks of the study.